Tatva Chintan Pharma Chem Limited — Q1FY27 Earnings Call Summary

TATVA · Q1FY27 · Filed 21 Jul 2026

Key Takeaways

• Board approved 200cr INR greenfield capex for multiproduct facility; revenue target 300cr INR at peak
• Q1 FY27 revenue 1,671mn INR +43% y-y, EBITDA 323mn INR +86% y-y
• FY27 revenue growth guidance 25-30%; EBITDA margin guidance 20-22%
• Semiconductor product qualified; commercial scale batch delivered; large opportunity expected
• Semiconductor commercialization expected post Q4 FY28; patience required for scale-up
• Structure Directing Agents demand strong; Euro 7 implementation driving growth
• Electrolyte Salts revenue impacted by raw material shortages; hybrid battery commercialization progressing
• Phase Transfer Catalysts revenue 428mn INR +38% q-q; growth driven by wider industry adoption
• Pharma & Agro Intermediates revenue 584mn INR +63% q-q; new pharma molecules commercializing
• Continuous flow chemistry adoption expanding; 7-8 products in pilot/commercial phase

📄 Source: View original transcript (PDF)

Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.